Evan Seigerman
Stock Analyst at BMO Capital
(1.58)
# 1365
Out of 5,287 analysts
156
Total ratings
48.78%
Success rate
14.73%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Biogen | Maintains: Market Perform | 156 139 | 141.6 | -1.84% | 18 | Feb 13, 2025 | |
Gilead Sciences | Maintains: Outperform | 110 115 | 106.83 | 7.65% | 15 | Feb 12, 2025 | |
Vertex Pharmaceutica... | Maintains: Outperform | 566 520 | 512.44 | 1.48% | 14 | Dec 20, 2024 | |
Bristol-Myers Squibb | Maintains: Market Perform | 57 61 | 61.09 | -0.15% | 11 | Nov 12, 2024 | |
Incyte | Reiterates: Underperform | 48 52 | 62.8 | -17.2% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 128 114 | 115.61 | -1.39% | 14 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 1001 1101 | 865.93 | 27.15% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 50 70 | 53.66 | 30.45% | 5 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 40 | 20.96 | 90.84% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 110 59 | n/a | n/a | 8 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 40 | 11.08 | 261.01% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 757 788 | 661.46 | 19.13% | 15 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 8 3 | 1.96 | 27.55% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 263 243 | 314.37 | -22.7% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 12 | 8.64 | 38.89% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 60 | 26.12 | 129.71% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 27 | 1.4 | 1828.57% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 7 | n/a | n/a | 4 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 9 15 | 0.03 | 49900% | 4 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 14 35 | n/a | n/a | 4 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underperform | 14 17 | n/a | n/a | 6 | Aug 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 13 30 | 1.96 | 1430.61% | 3 | May 12, 2020 |